The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and of (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (10 mV). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.本發明係關於包括(i)至少一種生物相容奈米粒子及(ii)至少一種包括至少一種醫藥化合物之載劑之組合之醫藥組合物，其欲投與需要此一醫藥化合物之個體，其中該至少一種生物相容奈米粒子與該至少一種包括該(等)醫藥化合物之載劑之該組合加強該(等)所關注化合物之效率。該生物相容奈米粒子之最長尺寸通常介於約4nm與約500nm之間，且其絕對表面電荷值係至少10mV(10mV)。另外，該載劑缺乏任何表面空間穩定劑。本發明亦係關於用於在有需要之個體中投與該(等)醫藥化合物之此一組合物，其中該至少一種生物相容奈米粒子及該至少一種包括該至少一種醫藥化合物之載劑欲在需要該醫藥化合物之個體中分開投與，彼此通常間隔介於超過5分鐘與約72小時之間。
